"Hungary Pharmaceuticals & Healthcare Report Q1 2016" Published

Hungary's pharmaceutical market represents a moderate but reliable commercial prospect within Central and Eastern Europe. The government plays a key role in the provision of medical services as demonstrated by its recent ban on parallel exports of medicines and the decentrali s ation of primary care. We nevertheless expect the private sector to become more involved over the medium term.

Headline Expenditure Projections

Pharmaceuticals: HUF648.10bn (USD2.79bn) in 2014 to HUF660.80bn (USD2.36bn) in 2015; +2.0% in local currency terms and -15.3% in US dollar terms.
Healthcare: HUF2.38trn (USD10.22bn) in 2014 to HUF2.42trn (USD8.65bn) in 2015; +1.9% in local currency terms and -15.3% in US dollar terms.
Risk/Reward Index

Full Report Details at
- http://www.fastmr.com/prod/1073388_hungary_pharmaceuticals.aspx?afid=302

Hungary currently ranks sixth (down from the fourth position in the previous quarter) out of the 20 regional markets profiled in the Central and Eastern Europe (CEE) region, with a score of 54.8. While its Risks profile is generally predictable. Concerns exist over respect for intellectual property protection and market barriers, with the country included in the Pharmaceutical Research and Manufacturers of America (PhRMA)'s special 301 submission for the fifth consecutive year in 2015. Hungary's Rewards score, however, has improved considerably due to favourable currency effects and our improving outlook for the country's pharmaceutical market.

The Hungary Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Hungary Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Hungary pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Hungary, to test other views - a key input for successful budgeting and strategic business planning in the Hungarian pharmaceutical and healthcare market.
* Target business opportunities and risks in the Hungarian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Hungary.
* Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View



About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Kenya Pharmaceuticals & Healthcare Report Q1 2016
- Thailand Pharmaceuticals & Healthcare Report Q1 2016
- Pakistan Pharmaceuticals & Healthcare Report Q1 2016
- Argentina Pharmaceuticals & Healthcare Report Q1 2016
- Croatia Pharmaceuticals & Healthcare Report Q1 2016